Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Transcept Pharmaceuticals General Information
Transcept Pharmaceuticals developed proprietary products in neuroscience, most notably Intermezzo (zolpidem tartrate sublingual tablet), which received FDA approval in 2011 for insomnia characterized by middle-of-the-night awakenings. The company licensed U.S. commercialization rights for Intermezzo to Purdue Pharma and was later acquired by Paratek Pharmaceuticals in 2014.
Contact Information
Primary Industry
Biotech
Corporate Office
King Of Prussia, Pennsylvania
USA
USA
Drug Pipeline
zolpidem tartrate
CommercialKey Partnerships
Purdue Pharma – exclusive U.S. licensee for commercialization of Intermezzo
Transcept Pharmaceuticals Funding
No funding data available
To view Transcept Pharmaceuticals's complete valuation and funding history, request access »